Latin America and the Caribbean vs Saudi Arabia: Percentage of bloodstream infection due to Escherichia coli resistant
Latin America and the Caribbean
30.9%
in 2022
Saudi Arabia
52.8%
in 2022
Latin America and the Caribbean rank
13th
Saudi Arabia rank
16th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Latin America and the Caribbean
- Saudi Arabia
How they compare
Saudi Arabia currently reports 52.8% against 30.9% in Latin America and the Caribbean, a difference of 21.9%.
That makes Saudi Arabia's figure about 1.7 times Latin America and the Caribbean's.
Across all 6 years both countries report, Saudi Arabia has been ahead every year.
Latin America and the Caribbean ranks 13th and Saudi Arabia ranks 16th of 16 groups.
Saudi Arabia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Latin America and the Caribbean | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20.2% | 54.3% | 34.1% | Saudi Arabia |
| 2020s | 28.3% | 54.7% | 26.3% | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Latin America and the Caribbean or Saudi Arabia?
- Saudi Arabia, at 52.8% against 30.9% in Latin America and the Caribbean as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Latin America and the Caribbean and Saudi Arabia?
- 21.9%, with Saudi Arabia ahead.
- How many years of comparable data are there for Latin America and the Caribbean and Saudi Arabia?
- 6 years are reported by both, from 2017 to 2022.
- How do Latin America and the Caribbean and Saudi Arabia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Latin America and the Caribbean ranks 13th and Saudi Arabia ranks 16th of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.